ESC 365 - Mineralcorticoid-antagonists in chronic kidney disease and Type 2 Diabetes: Key clinical findings from current studies.

Open Access

Mineralcorticoid-antagonists in chronic kidney disease and Type 2 Diabetes: Key clinical findings from current studies.

Session: Improving cardiovascular and renal outcomes in diabetic kidney disease

Topic: Chronic Kidney Disease

Speaker: Professor R. Schmieder (Erlangen, DE)

Sponsored by Sciarc GmbH

Event: Heart Failure 2021

Congress Presentation

About the speaker

Professor Roland Schmieder

University Hospital Erlangen, Erlangen (Germany)

25 presentations

0 follower

3 more presentations in this session

Welcome and introduction.

Speaker: Professor S. Anker (Berlin, DE)

Finerenone in reducing mortality and morbidity in diabetic kidney disease

Speaker: Professor G. Filippatos (Athens, GR)

Discussion and closure.

Access the full session

Improving cardiovascular and renal outcomes in diabetic kidney disease

Speakers: Professor R. Schmieder, Professor S. Anker, Professor G. Filippatos

About the event

Heart Failure 2021

29 June - 1 July 2021

Sessions Presentations

Congress

Related content

ESC Premium Access

Rethinking coronary artery disease: diagnosis and treatment.

27 August 2021

ESC Premium Access

Replacing the pill: the future of CVD therapy.

27 August 2021

ESC Premium Access

The ECG and beyond: artificial intelligence will penetrate cardiology practice.

27 August 2021

ESC 365 is supported by